TRIB secures major regulatory nod for Uni-Gold rapid HIV test production

Rhea-AI Filing Summary

Trinity Biotech plc filed a Form 6-K to report that, on November 18, 2025, it issued a press release announcing a major regulatory approval related to manufacturing of its Uni-Gold rapid HIV test. The approval covers offshored and outsourced production of this market-leading diagnostic product.

The company describes this step as part of a broader effort to transform its financial performance, suggesting that the new manufacturing structure is intended to support that strategy. Details of the approval and its expected impact are contained in the press release attached as Exhibit 99.1.

Insights

Healthcare and diagnostics industry analyst

Regulatory clearance enables offshored, outsourced production of Uni-Gold HIV test.

Trinity Biotech reports a major regulatory approval allowing offshored and outsourced manufacturing of its Uni-Gold rapid HIV test. Uni-Gold is described as a market-leading HIV diagnostic, so changes to how it is produced can be strategically important for costs, capacity, and supply reliability.

Moving to offshored and outsourced manufacturing often aims to optimize production economics and flexibility, though the exact terms and locations are not detailed here. The company links this step to its ongoing financial performance transformation, indicating that the approval is intended to support broader profitability and efficiency goals.

Investors may focus on future disclosures that quantify how this new manufacturing setup affects margins and volumes for the Uni-Gold product line, especially in periods after November 18, 2025, when the approval was announced.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of

Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).

EXPLANATORY NOTE

On November 18, 2025, the Company issued a press release announcing it has secured major regulatory approval for offshored and outsourced manufacturing of its market leading Uni-Gold rapid HIV test. A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ John Gillard
		John Gillard
		Chief Executive Officer

Date:  November 21, 2025

FAQ

What did Trinity Biotech (TRIB) announce in this Form 6-K?

Trinity Biotech reported that it issued a press release on November 18, 2025 announcing a major regulatory approval for offshored and outsourced manufacturing of its Uni-Gold rapid HIV test.

Which Trinity Biotech product is affected by the new regulatory approval?

The approval relates to the companys market leading Uni-Gold rapid HIV test, specifically allowing its manufacturing to be offshored and outsourced.

How does Trinity Biotech describe the impact of this approval on its business?

In the exhibit description, Trinity Biotech links the approval to further accelerating financial performance transformation, indicating it views the manufacturing change as part of its broader financial improvement strategy.

When was the press release about the regulatory approval issued by Trinity Biotech?

The company issued the press release on November 18, 2025, and it is attached to the Form 6-K as Exhibit 99.1.

Who signed the Form 6-K for Trinity Biotech plc?

The Form 6-K was signed on behalf of Trinity Biotech plc by John Gillard, who is identified as the Chief Executive Officer.

What exhibit is included with this Trinity Biotech (TRIB) Form 6-K?

The filing includes Exhibit 99.1, titled Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation.